Association of Clinical Research Professionals

acrpnet.org

In clinical research, people are everything. ACRP raises clinical research standards and accelerates careers. Better People. Better Results. ACRP is where gold standard clinical researchers begin. And belong. – Being part of the ACRP community means you are the gold standard in clinical research, and you have the qualifications to prove it. With support and tools to help you every step of the way, ACRP springboards your career onwards and upwards.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

SPOTLIGHT THERAPEUTICS APPOINTS VISIONARY GLOBAL PHARMA DRUG DEVELOPER ANTOINE YVER, M.D., M.SC. AS FIRST INDEPENDENT BOARD MEMBER

Spotlight Therapeutics | July 18, 2022

news image

Spotlight Therapeutics, Inc. a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, announced the appointment of Antoine Yver, M.D., M.Sc. to the Spotlight Board of Directors. Trained as an oncologist and immunologist, Dr. Yver’s extensive industry experience and perceptive acumen will be extremely valuable as Spotlight continues to strengthen its highly differentiated TAGE platform and advance lead therapeutic candidates towards the c...

Read More

Pharma Tech

EYENOVIA ANNOUNCES $15 MILLION CREDIT FACILITY WITH AVENUE VENTURE DEBT FUND

Eyenovia, Inc. | November 30, 2022

news image

Eyenovia, Inc. a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the company has entered into a $15 million credit facility with the Avenue Venture Opportunities Fund, L.P. The financing is intended to support manufacturing in anticipation of a MydCombi laun...

Read More

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

news image

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More

Business Insights

LABCORP PLANS LABORATORY EXPANSION IN JAPAN THROUGH BML COLLABORATION

Labcorp | July 04, 2022

news image

Labcorp a leading global life sciences company, announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services. Extending their strategic relationship that dates back more than a decade, Labcorp Drug Development and BML will begin work on a new laboratory fa...

Read More
news image

Business Insights

SPOTLIGHT THERAPEUTICS APPOINTS VISIONARY GLOBAL PHARMA DRUG DEVELOPER ANTOINE YVER, M.D., M.SC. AS FIRST INDEPENDENT BOARD MEMBER

Spotlight Therapeutics | July 18, 2022

Spotlight Therapeutics, Inc. a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, announced the appointment of Antoine Yver, M.D., M.Sc. to the Spotlight Board of Directors. Trained as an oncologist and immunologist, Dr. Yver’s extensive industry experience and perceptive acumen will be extremely valuable as Spotlight continues to strengthen its highly differentiated TAGE platform and advance lead therapeutic candidates towards the c...

Read More
news image

Pharma Tech

EYENOVIA ANNOUNCES $15 MILLION CREDIT FACILITY WITH AVENUE VENTURE DEBT FUND

Eyenovia, Inc. | November 30, 2022

Eyenovia, Inc. a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the company has entered into a $15 million credit facility with the Avenue Venture Opportunities Fund, L.P. The financing is intended to support manufacturing in anticipation of a MydCombi laun...

Read More
news image

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More
news image

Business Insights

LABCORP PLANS LABORATORY EXPANSION IN JAPAN THROUGH BML COLLABORATION

Labcorp | July 04, 2022

Labcorp a leading global life sciences company, announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services. Extending their strategic relationship that dates back more than a decade, Labcorp Drug Development and BML will begin work on a new laboratory fa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us